Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2006 1
2008 2
2009 2
2010 3
2011 4
2012 5
2013 8
2014 4
2015 12
2016 16
2017 18
2018 21
2019 16
2020 9
2021 12
2022 8
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30590833

127 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
Paccaly AJ, Kovalenko P, Parrino J, Boyapati A, Xu C, van Hoogstraten H, Ishii T, Davis JD, DiCioccio AT. Paccaly AJ, et al. J Clin Pharmacol. 2021 Jan;61(1):90-104. doi: 10.1002/jcph.1703. Epub 2020 Jul 29. J Clin Pharmacol. 2021. PMID: 32726514 Free PMC article. Clinical Trial.
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TWJ, van der Heijde D; EXTEND study investigators. Genovese MC, et al. Rheumatology (Oxford). 2018 Aug 1;57(8):1423-1431. doi: 10.1093/rheumatology/key121. Rheumatology (Oxford). 2018. PMID: 29746672 Free PMC article. Clinical Trial.
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR. Fleischmann R, et al. Arthritis Rheumatol. 2017 Feb;69(2):277-290. doi: 10.1002/art.39944. Arthritis Rheumatol. 2017. PMID: 27860410 Free PMC article. Clinical Trial.
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, van Adelsberg J, Weinstein SP, Graham NM, Stahl N, Yancopoulos GD, Huizinga TW, van der Heijde D. Genovese MC, et al. Arthritis Rheumatol. 2015 Jun;67(6):1424-37. doi: 10.1002/art.39093. Arthritis Rheumatol. 2015. PMID: 25733246 Clinical Trial.
Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis.
Kovalenko P, Paccaly A, Boyapati A, Xu C, St John G, Nivens MC, Davis JD, Rippley R, DiCioccio AT. Kovalenko P, et al. CPT Pharmacometrics Syst Pharmacol. 2020 Jul;9(7):405-416. doi: 10.1002/psp4.12534. Epub 2020 Jun 20. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32453485 Free PMC article.
127 results